Sarilumab
Brand Names: Kevzara
Methodology & AI Transparency ⓘ
Sarilumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 200 mg/1.14mL Injection, Solution and 150 mg/1.14mL Injection, Solution and manufactured/labeled by Sanofi-Aventis U.S.
- 2 Real-world patient consensus: Zero-PHI community consensus: 77% favorable across 7 logged regimens (Kevzara).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Sarilumab include nausea (8.9%), headache (8.4%), dizziness (5.7%).
Ask our AI Specialists anything about Sarilumab
Sarilumab Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 200 mg/1.14mL Injection, Solution and 150 mg/1.14mL Injection, Solution and manufactured/labeled by Sanofi-Aventis U.S. LLC (NDC 0024-5922, 0024-5910), Sarilumab operates within subcutaneous-route interleukin-6 receptor antagonist treatment algorithms requiring prescription authorization.
Delivered via 200 mg/1.14mL Injection, Solution and 150 mg/1.14mL Injection, Solution (subcutaneous-route; NDC 0024-5922, 0024-5910), Sarilumab mediates interleukin-6 receptor antagonist physiological effects manufactured/labeled by Sanofi-Aventis U.S. LLC with dose-dependent receptor occupancy and systemic clearance.
Clinical clearance of Sarilumab (Interleukin-6 Receptor Antagonist) relies on predominantly hepatic biotransformation with renal elimination of polar sarilumab conjugates with a Steady-state plasma equilibrium reached over 6–13 hour t½ intervals for Sarilumab half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Sarilumab (200 mg/1.14mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after sarilumab administration.
FDA clinical labeling for Sarilumab restricts administration in contraindicated in patients with prior serious allergic response to sarilumab (ndc 0024-5922); severe baseline organ impairment where sarilumab accumulation exceeds safe therapeutic margins across 200 mg/1.14mL Injection, Solution, 150 mg/1.14mL Injection, Solution, with self-reported patient tracking dominated by nausea (8.9% of reports), headache (8.4% of reports), fatigue (5.7% of reports).
Reconcile eGFR-adjusted medications before escalating Sarilumab in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Sarilumab maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Sarilumab (NDC 0024-5922)
- Severe baseline organ impairment where Sarilumab accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (7 Reports)
Sarilumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sarilumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Deciphering differential biomarkers for anti-interleukin-6 receptor and: What a 804-Participant Study Found The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-α at different timepoints that could explain the difference in the response rate in patients with RA. RMD open • 2025-08-04 • Phase III Randomized Trial | N = 804 | 93/100 | PMID 40759562 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of sarilumab on unacceptable pain and inflammation control in Japanese Sarilumab treatment reduced UP and inflammation in Japanese patients with autoimmune joint pain (autoimmune joint pain (rheumatoid arthritis)). Modern rheumatology • 2024-07-06 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37606691 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase 3 randomized, gold-standard blind, compared against a dummy pill Owing to the small sample size due to the early termination, it is difficult to draw clear conclusions from this study. Arthritis research & therapy • 2023-10-16 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37840134 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity of sarilumab and impact on safety and real-world benefits in ADAs, which occurred at a low frequency and titre, did not affect the safety or efficacy of sarilumab 150 or 200 mg administered as single-drug treatment or combination therapy in Japanese patients with RA in the KAKEHASI or... Modern rheumatology • 2022-07-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34915576 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of sarilumab in patients with autoimmune joint pain In Japanese patients with RA enrolled in Phase 3 studies for sarilumab, no clear difference in efficacy or safety was observed between patients aged <65 and ≥65 years. Modern rheumatology • 2024-12-25 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39073574 ↗ |
Sarilumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2071.2294/unit (~$62136.88/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Sarilumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sarilumab RxNorm Concept ID | RXN-00245922-2667 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2071.2294 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sarilumab Patient Community, Cohort Filters & Dosage Logs
Deterministic Sarilumab reference combining NIH RxNorm (RXN-00245922-2667), Medicaid NADAC ($2071.2294/unit), and anonymous cohort outcomes (77% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sarilumab community threads and patient logs by age, biological sex, dosage, and treatment duration.